

Oncopeptides Operational Update May 21, 2019

Jakob Lindberg, CEO



Disclaimer

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Oncopeptides AB (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “Information”). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is confidential and may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. This document may not be removed from the premises. If this document has been received in error it must be returned immediately to the Company.

The Information is not intended for potential investors and does not constitute or form part of, and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained therein shall form the basis of or be relied on in connection with any contract or commitment whatsoever. This document and its contents may not be viewed by persons within the United States or “U.S. Persons” (as defined in Regulation S under the Securities Act of 1933, as amended (the “Securities Act”) unless they are qualified institutional buyers “QIBs” as defined in Rule 144A under the Securities Act. By accessing the Information, you represent that you are (i): a non-U.S. person that is outside the United States or (ii) a QIB. This document and its contents may not be viewed by persons within the United Kingdom unless they are persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”), or high net worth entities falling within Article 49(2)(a) to (d) of the Order (each a “Relevant Person”). By accessing the Information, you represent that you are: (i) outside the United Kingdom or (ii) a Relevant Person.


The Information has been prepared by the Company, and no other party accepts any responsibility whatsoever, or makes any representation or warranty, express or implied, for the contents of the Information, including its accuracy, completeness or verification or for any other statement made or purported to be made in connection with the Company and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future.

No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company’s expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

Application for accelerated approval


- Oncopeptides has been engaged in dialogue with the FDA during the spring of 2019
- FDA has had access to all data from our ongoing and completed trials (apart from OCEAN)
- Based on the dialogue, Oncopeptides has now initiated the submission process for accelerated approval in the US
 - Treatment of relapsed refractory multiple myeloma patients whose disease is triple-class refractory (i.e. refractory to one IMiD, one PI and one anti-CD38 Mab)
- Target filing date is Q1 2020



Overview of our present clinical development program in multiple myeloma



Financial results for the period Jan – Mar 2019



- Operating loss increased to SEK 121.9 M (loss:62.0)
 - R&D incr. primarily due to incr. in Clin.&drug supply: SEK 73.1 M (46.8)
 - OCEAN costs SEK 37.6 M (29.8)
 - ANCHOR costs SEK 13.2 M (3.5)
 - HORIZON costs SEK 11.0 (5.3)
 - Build-up of commercial and medical relations explains increase in M&S costs
- Operating costs include non-cash costs related to incentive programs
 - SEK 7.9 M (2.4) for q1
- Cash flow from operating activities neg. SEK 142.8 M (neg. 40.6)
 - Cash flow from financing activities SEK 514.0 M (295.0)
- Cash position was SEK 747.5 M (664.9) as of March 31, 2019
 - Directed share issue raised SEK 514.8 M after issue costs in January, 2019

EHA is a major event for us

- One oral presentation by Prof. Paul Richardsson regarding HORIZON
- Three poster presentations regarding ANCHOR, parameters of health economic importance from O-12-M1 as well as a safety review in RRMM (not only melflufen)
- One satellite symposia (see below)

Challenging the Treatment Paradigm in **MULTIPLE MYELOMA**

*An Industry-Supported Satellite Symposium During
the 24th Congress of the European Hematology Association*

13 June 2019

18:45 Registration and Buffet

19:15 — 20:45 Meeting




Chair
Xavier Leleu, MD, PhD

Faculty
Meletios A. Dimopoulos, MD
Faith Davies, MD
Paul G. Richardson, MD

Amsterdam RAI
Hall 38 | Europaplein 24, 1078 GZ
Amsterdam, The Netherlands

 oncopeptides



Upcoming newsflow – highly exciting year ahead of us

H1 2019	H2 2019	H1 2020
Data from ANCHOR and HORIZON at AACR	FPI Amyloidosis Trial	NDA submission
Updated data from ANCHOR and HORIZON at EHA	FPI LIGHTHOUSE	LPI OCEAN
FDA meeting on HORIZON	LPI HORIZON	LPI ANCHOR
O-12-M1 publication	LPI BRIDGE	Top-line results OCEAN
	Updated Data from HORIZON, ANCHOR and BRIDGE at ASH	

***Thank you for
your attention!***

